Jang HR, Lee HY, Song SY, Lim KH. Clinical outcomes of targeted therapies in elderly patients aged ≥ 80 years with metastatic colorectal cancer. World J Clin Cases 2022; 10(28): 10066-10076 [PMID: 36246797 DOI: 10.12998/wjcc.v10.i28.10066]
Corresponding Author of This Article
Kyu-Hyoung Lim, MD, PhD, Professor, Department of Internal Medicine, Kangwon National University Hospital, Kangwon National University School of Medicine, Chuncheon-si, 156 Baengnyeong-ro, Gangwon-do 24289, South Korea. kyuhyoung.lim@kangwon.ac.kr
Research Domain of This Article
Oncology
Article-Type of This Article
Retrospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Hee Ryeong Jang, Hui-Young Lee, Seo-Young Song, Kyu-Hyoung Lim, Department of Internal Medicine, Kangwon National University Hospital, Kangwon National University School of Medicine, Chuncheon-si, Gangwon-do 24289, South Korea
Author contributions: Lim KH contributed to design and data analysis, drafted the manuscript, contributed to the conception and critically revised the manuscript; Jang HR contributed to data analysis and critically revised the manuscript; Jang HR, Lee HY, Song SY contributed to data acquisition and analysis; all authors read and approved the final manuscript.
Institutional review board statement: The study was performed in full accordance with the precepts of the Declaration of Helsinki. This study was approved by the Institutional Review Board of Kangwon National University Hospital (IRB No: KNUH-2021-03-008).
Informed consent statement: Patients’ consents were waived from the institutional review board.
Conflict-of-interest statement: All authors declare that there is no conflict of interest.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Kyu-Hyoung Lim, MD, PhD, Professor, Department of Internal Medicine, Kangwon National University Hospital, Kangwon National University School of Medicine, Chuncheon-si, 156 Baengnyeong-ro, Gangwon-do 24289, South Korea. kyuhyoung.lim@kangwon.ac.kr
Received: June 7, 2022 Peer-review started: June 7, 2022 First decision: July 12, 2022 Revised: July 26, 2022 Accepted: August 17, 2022 Article in press: August 17, 2022 Published online: October 6, 2022 Processing time: 112 Days and 8.1 Hours
ARTICLE HIGHLIGHTS
Research background
The efficacy and safety of combination chemotherapy for metastatic colorectal cancer (CRC) in extremely elderly patients has yet to be established.
Research motivation
Combination chemotherapy with targeted agent (TA) for metastatic CRC may be considered feasible in patients aged above 80 years.
Research objectives
To assess the clinical outcomes and feasibility of combination chemotherapy using a TA in extremely elderly patients with CRC.
Research methods
Total 30 patients over 80 years of age with metastatic CRC were retrospectively reviewed.
Research results
The median progression-free survival and overall survival in patients treated with TA were 7.4 mo and 15.4 mo, respectively, compared with 4.4 mo and 15.6 mo in patients treated without TA.
Research conclusions
Combination chemotherapy with TA for metastatic CRC may be considered even in elderly patients over 80 years of age with considerable caution for chemotherapy-related toxicity and risk of comorbidities.
Research perspectives
This study may help to understand the role of targeted therapy and the potential of combination chemotherapy in extremely elderly patients with metastatic CRC.
